SEC Filing Timeline
S-3Aug 31, 2026
Shelf registration
10-QAug 05, 2026
Quarterly report
8-KAug 05, 2026
Executive officer change · Items 2.02,5.02,9.01
8-KJun 18, 2026
Shareholder vote results · Items 5.07
424B5May 26, 2026
Prospectus / offering
8-KMay 26, 2026
Material agreement · Items 1.01,8.01,9.01
8-KMay 26, 2026
Other material event · Items 8.01
424B5May 26, 2026
Prospectus / offering
8-KMay 26, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KMay 14, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
10-QMay 05, 2026
Quarterly report
8-KMay 05, 2026
Earnings release · Items 2.02,9.01
DEFA14AApr 28, 2026
Additional proxy
DEF 14AApr 28, 2026
Proxy statement
8-KApr 07, 2026
Financial exhibits · Items 4.01,9.01
Recent News (Finnhub)
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?